RxSight (NASDAQ:RXST – Get Free Report) is scheduled to release its earnings data after the market closes on Monday, August 5th. Analysts expect RxSight to post earnings of ($0.07) per share for the quarter. RxSight has set its FY 2024 guidance at EPS.Individual that wish to register for the company’s earnings conference call can do so using this link.
RxSight (NASDAQ:RXST – Get Free Report) last announced its quarterly earnings results on Monday, May 6th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.08). The firm had revenue of $29.51 million during the quarter, compared to analysts’ expectations of $27.56 million. RxSight had a negative net margin of 44.01% and a negative return on equity of 27.68%. The company’s quarterly revenue was up 68.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.42) EPS. On average, analysts expect RxSight to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
RxSight Stock Down 5.9 %
NASDAQ:RXST opened at $41.77 on Friday. RxSight has a 52-week low of $20.66 and a 52-week high of $66.54. The stock has a fifty day simple moving average of $53.84 and a 200-day simple moving average of $53.42. The company has a market capitalization of $1.55 billion, a PE ratio of -33.15 and a beta of 1.19.
Wall Street Analysts Forecast Growth
View Our Latest Research Report on RXST
Insider Activity
In other RxSight news, CFO Shelley B. Thunen sold 10,000 shares of the firm’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $58.61, for a total value of $586,100.00. Following the sale, the chief financial officer now directly owns 13,938 shares of the company’s stock, valued at approximately $816,906.18. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, Director Julie Andrews sold 15,625 shares of the company’s stock in a transaction on Friday, June 14th. The stock was sold at an average price of $58.00, for a total transaction of $906,250.00. Following the completion of the sale, the director now directly owns 30,287 shares in the company, valued at approximately $1,756,646. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Shelley B. Thunen sold 10,000 shares of RxSight stock in a transaction on Monday, July 1st. The shares were sold at an average price of $58.61, for a total value of $586,100.00. Following the completion of the transaction, the chief financial officer now owns 13,938 shares in the company, valued at approximately $816,906.18. The disclosure for this sale can be found here. Company insiders own 9.36% of the company’s stock.
About RxSight
RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.
Read More
- Five stocks we like better than RxSight
- Which Wall Street Analysts are the Most Accurate?
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
- Are Penny Stocks a Good Fit for Your Portfolio?
- Intel Loses a Quarter of Its Value After Horrible Earnings Report
Receive News & Ratings for RxSight Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RxSight and related companies with MarketBeat.com's FREE daily email newsletter.